Metabolic memory - The implications for diabetic complications

Endokrynologia Polska

Volumn 61, Issue 6, 2010, Pages 700-703

  Otto Buczkowska, Ewa ^a   Machnica, Łukasz ^a  

^a Upper Silesian Center of Children's Health in Katowice   (Poland)

Author keywords

Diabetic complications; Levels of glucose; Metabolic memory

Indexed keywords

CELL PROTEIN; POLYOL; PROTEIN KINASE C; PROTEOGLYCAN;

BLOOD GLUCOSE MONITORING; DIABETES MELLITUS; ENZYME ACTIVATION; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HUMAN; HYPERGLYCEMIA; OXIDATIVE STRESS; PROTEIN GLYCOSYLATION; REVIEW;

DIABETES COMPLICATIONS; HUMANS; LIPID METABOLISM; MEMBRANE PROTEINS; OXIDATIVE STRESS; PREDIABETIC STATE;

EID: 78650003000     PISSN: 0423104X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (34)

1. Schlotterer A, Kukudov G, Bozorgmehr F et al. C. elegans as model for the study of high glucose- mediated life span reduction. Diabetes 2009; 58: 2450-2456.
2. Turk Z. Glycotoxines, carbonyl stress and relevance to diabetes and its complications. Physiol Res 2010; 59: 147-156.
3. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. N Engl J Med 2000; 342: 381-389.
4. White NH, Geary PA, Dahms W et al.; Diabetes Control and Complications Trial (DCCT)/Epidemiology of Diabetes Interventions and Complications (EDIC) Research Group. Beneficial effects of intensive therapy of diabetes during adolescence: outcomes after the conclusion of the Diabetes Control and Complications Trial (DCCT). J Pediatr 2001; 139: 804-812.
5. Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus. JAMA 2002; 287: 2563-2569.
6. de Boer IH, Kestenbaum B, Rue TC et al.; Diabetes Control and Complications Trial (DCCT)/Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Group. Insulin therapy, hyperglycemia, and hypertension in type 1 diabetes mellitus. Arch Intern Med 2008; 168: 1867-1873.
7. Genuth S. Insights from the diabetes control and complications trial/epidemiology of diabetes interventions and complications study on the use of intensive glycemic treatment to reduce the risk of complications of type 1 diabetes. Endocr Pract 2006; 12 (Suppl. 1): 34-41. (Pubitemid 44963609)
8. Ihnat MA, Thorpe JE, Ceriello A. Hypothesis: the "metabolic memory", the new challenge of diabetes. Diabet Med 2007; 24: 582-586.
9. Kilpatrick ES, Rigby AS, Atkin SL. The Diabetes Control and Complications Trial: the gift that keeps giving. Nat Rev Endocrinol 2009; 5: 537-545.
10. Marcovecchio ML, Tossavainen PH, Dunger DB. Prevention and treatment of microvascular disease in childhood type 1 diabetes Br Med Bull 2010; 6 [Epub ahead of print].
11. Nordwall M, Arnqvist HJ, Bojestig M et al. Good glycemic control remains crucial in prevention of late diabetic complications - the Linköping Diabetes Complications Study. Pediatr Diabetes 2009; 10: 168-176.
12. Pop-Busui R, Low PA, Waberski BH et al.; DCCT/EDIC Research Group. Effects of prior intensive insulin therapy on cardiac autonomic nervous system function in type 1 diabetes mellitus: the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications study (DCCT/EDIC). Circulation 2009; 119: 2886-2893.
13. White NH, Sun W, Cleary PA et al. Prolonged effect of intensive therapy on the risk of retinopathy complications in patients with type 1 diabetes mellitus: 10 years after the Diabetes Control and Complications Trial. Arch Ophthalmol 2008; 126: 1707-1715.
14. Villeneuve LM, Natarajan R. The role of epigenetics in the pathology of diabetic complications. Am J Physiol Renal Physiol 2010; 299: F14-F25.
15. Ceriello A. Hypothesis: the "metabolic memory", the new challenge of diabetes. Diabetes Res Clin Pract 2009; 86 (Suppl. 1): S2-S6.
16. Siebel AL, Fernandez AZ, El-Osta A. Glycemic memory associated epigenetic changes. Biochem Pharmacol 2010; 19 [Epub ahead of print].
17. Tonna S, El-Osta A, Cooper ME et al. Metabolic memory and diabetic nephropathy: potential role for epigenetic mechanisms. Nat Rev Nephrol 2010; 6: 332-341.
18. Zhong Q, Kowluru RA. Role of histone acetylation in the development of diabetic retinopathy and the metabolic memory phenomenon. J Cell Biochem 2010; 110: 1306-1313.
19. Ihnat MA, Thorpe JE, Ceriello A. Hypothesis: the "metabolic memory", the new challenge of diabetes. Diabet Med 2007; 24: 582-586.
20. Ceriello A, Ihnat MA, Thorpe JE. Clinical review 2: The "metabolic memory": is more than just tight glucose control necessary to prevent diabetic complications? J Clin Endocrinol Metab 2009; 94: 410-115.
21. Drzewoski J, Kasznicki J, Trojanowski Z. The role of "metabolic memory" in the natural history of diabetes mellitus. Pol Arch Med Wewn 2009; 119: 493-500.
22. Pietkiewicz J, Seweryn E, Bartyś A et al. Receptory końcowych produktów zaawansowanej glikacji - znaczenie fizjologiczne i kliniczne. Postepy Hig Med Dosw (online) 2008; 62: 511-523.
23. Piwowar A. Advanced oxidation protein products. Part I. Mechanism of the formation, characteristics and property. Pol Merkur Lekarski. 2010; 28: 166-169.
24. Yao D, Brownlee M. Hyperglycemia-induced reactive oxygen species increase expression of the receptor for advanced glycation end products (RAGE) and RAGE ligands. Diabetes 2010; 59: 249-255.
25. Yan SF, Ramasamy R, Schmidt AM. Mechanisms of disease: advanced glycation end-products and their receptor in inflammation and diabetes complications. Nat Clin Pract Endocrinol Metab 2008; 4: 285-293. (Pubitemid 351571138)
26. Zorov DB, Juhaszona M, Sollott SJ. Mitochondria ROS-induced ROS release. An update and review. Biochim Biophys Acta 2006; 1757: 509-517.
27. Yamagishi S, Matsui T. Smooth muscle cell pathophysiology and advanced glycation end products (AGEs). Curr Drug Targets 2010; 11: 875-881.
28. Jabłońska-Trypuć A. Molekularny mechanizm nieenzymatycznej glikacji bialek i jej rofa w cukrzycy. Przegla̧d Kardiodiabetologiczny 2007; 24: 253-258.
29. Kowluru RA, Zhong Q, Kanwar M. Metabolic memory and diabetic retinopathy: role of inflammatory mediators in retinal pericytes. Exp Eye Res 2010; 90: 617-623.
30. Karolewska-Kuszej M, Drożdz J. Zmiany w czynności środblonka naczyniowego u chorych kardiologicznych z poś ledzona̧ tolerancja̧ glukozy. Przegla̧d Kardiodiabetologiczny 2007; 2: 133-138.
31. Pupek-Musialik D, Kujawska-Łuczak M. Patogeneza nadciśnienia tȩtniczego w cukrzycy. Przegla̧d Kardiodiabetologiczny 2007; 2: 88-97.
32. Krzystek-Korpacka M, Salmonowicz B, Boehm D et al. Diagnostic potential of oxidative stress markers in children and adolescents with type 1 diabetes. Clin Biochem 2008; 41: 48-55. (Pubitemid 350216832)
33. Giugliano D, Ceriello A, Esposito K. Glucose metabolism and hyperglycemia. Am J Clin Nutr 2008; 87: 217S-222S.
34. Cooper ME. Metabolic memory: implications for diabetic vascular complications. Pediatr Diabetes 2009; 10: 343-346.